$58.23 0.6%
CTLT Stock Price vs. AI Score
Data gathered: July 23

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies; Biologics and Specialty Drug Delivery; Oral Drug Delivery; and Clinical Supply Services. The Softgel Technologies segment formulate, develop, and manufacture services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufacture services for blow-fill-seal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies, and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules, and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution, and inventory management for drugs and biologics in clinical trials.


Catalent
Price $58.23
Target Price Sign up
Volume 1,880,000
Market Cap $10.5B
Year Range $37.18 - $59.82
Dividend Yield 0%
PE Ratio 209.17
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '241.07B845M229M-101M44M-0.060
Q4 '231.02B853M171M-206M-57M-0.240
Q3 '23982M813M169M-759M-683M-0.100
Q2 '231.06B840M215M-110M-20M0.090
Q1 '231.04B857M180M-227M-174M-0.090

Insider Transactions View All

Masanovich Matti filed to sell 33,871 shares at $56.7.
July 10 '24
Hopson Ricky filed to sell 20,617 shares at $54.3.
June 5 '24
Gunther Scott filed to sell 29,506 shares at $56.2.
March 19 '24
Ryan Michelle R filed to buy 1,979 shares at $50.
September 5 '23
GREISCH JOHN J filed to buy 34,000 shares at $50.2.
September 1 '23

Congress Trading View All

Politician Filing Date Type Size
Rohit Khanna
Democrat
Jun 5, 24 Sell $1K - $15K
Rohit Khanna
Democrat
May 6, 24 Buy $1K - $15K
Rohit Khanna
Democrat
Jun 12, 23 Sell $1K - $15K

What is the Market Cap of Catalent?

The Market Cap of Catalent is $10.5B.

What is Catalent's PE Ratio?

As of today, Catalent's PE (Price to Earnings) ratio is 209.17.

What is the current stock price of Catalent?

Currently, the price of one share of Catalent stock is $58.23.

How can I analyze the CTLT stock price chart for investment decisions?

The CTLT stock price chart above provides a comprehensive visual representation of Catalent's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Catalent shares. Our platform offers an up-to-date CTLT stock price chart, along with technical data analysis and alternative data insights.

Does CTLT offer dividends to its shareholders?

As of our latest update, Catalent (CTLT) does not offer dividends to its shareholders. Investors interested in Catalent should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Catalent?

Some of the similar stocks of Catalent are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.